Login to Your Account



Invitrogen Paying $47M In Cash For Software Provider InforMax

By Randall Osborne


Wednesday, October 16, 2002
Invitrogen Corp. aims to create a "desktop to lab bench" tool set with its buyout of InforMax Inc. in an all-cash transaction valued at $1.36 per share, or about $42 million for the fully diluted equity. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription